Breast Cancer Metastatic

Oncology
9
Pipeline Programs
7
Companies
7
Clinical Trials
2 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
3
0
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

ADC
267%
Monoclonal Antibody
133%
+ 6 programs with unclassified modality

On Market (1)

Approved therapies currently available

AstraZeneca
LYNPARZAApproved
olaparib
AstraZeneca
oral2014

Competitive Landscape

7 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
2 programs
1
1
1
OlaparibPhase 3
trastuzumab derxutecanPhase 21 trial
Active Trials
NCT06680596Enrolling By Invitation80Est. Aug 2029
M&
Merck & Co.RAHWAY, NJ
1 program
1
OlaparibPhase 31 trial
Active Trials
NCT02000622Completed302Est. Dec 2025
DS
Daiichi SankyoChina - Shanghai
2 programs
1
1
Trastuzumab DeruxtecanPhase 2ADC1 trial
Patritumab deruxtecanPhase 1/2ADC1 trial
Active Trials
NCT06298084Recruiting152Est. Jun 2029
NCT06750484Recruiting40Est. Dec 2028
Zai Lab
Zai LabCA - South SF
1 program
1
MargetuximabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT04262804Unknown123Est. Dec 2023
Bayer
BayerLEVERKUSEN, Germany
1 program
1
Combination, Rogaratinib + palbociclib + fulvestrantPhase 1
Pfizer
PfizerNEW YORK, NY
1 program
1
PF-03084014Phase 11 trial
Active Trials
NCT01876251Terminated30Est. Dec 2015
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
patient-reported-outcomesN/A1 trial
Active Trials
NCT03132506Completed106Est. Jul 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Merck & Co.Olaparib
AstraZenecatrastuzumab derxutecan
Daiichi SankyoTrastuzumab Deruxtecan
Zai LabMargetuximab
Daiichi SankyoPatritumab deruxtecan
PfizerPF-03084014
Heidelberg Pharmapatient-reported-outcomes

Clinical Trials (7)

Total enrollment: 833 patients across 7 trials

NCT02000622Merck & Co.Olaparib

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

Start: Mar 2014Est. completion: Dec 2025302 patients
Phase 3Completed
NCT06680596AstraZenecatrastuzumab derxutecan

Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy

Start: Jul 2025Est. completion: Aug 202980 patients
Phase 2Enrolling By Invitation
NCT06750484Daiichi SankyoTrastuzumab Deruxtecan

Trial of Trastuzumab Deruxtecan in Previously Treated HER2

Start: Jun 2025Est. completion: Dec 202840 patients
Phase 2Recruiting
NCT04262804Zai LabMargetuximab

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Start: Jan 2020Est. completion: Dec 2023123 patients
Phase 2Unknown
NCT06298084Daiichi SankyoPatritumab deruxtecan

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd

Start: Mar 2024Est. completion: Jun 2029152 patients
Phase 1/2Recruiting
NCT01876251PfizerPF-03084014

A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

Start: Nov 2013Est. completion: Dec 201530 patients
Phase 1Terminated
NCT03132506Heidelberg Pharmapatient-reported-outcomes

E-Health Portal for Individualized Treatment Monitoring and Patient Engagement in Oncology Research

Start: Jun 2017Est. completion: Jul 2024106 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 833 patients
7 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)